Niche Neurology Focus Auspex concentrates on movement disorders and orphan diseases, presenting opportunities for licensing or co-development with larger pharma seeking selective neurology assets.

Legacy Teva Tie Historical acquisition by Teva for 3.5B and the deutetrabenazine asset highlight the value big pharma places on rare-disease neurology programs, signaling potential for new partnerships or out-licensing of the pipeline.

Orphan Market Potential Pipeline aimed at orphan indications can help engage specialty payers and patient advocacy groups, with possibilities for faster regulatory pathways and premium pricing in the U.S.

Agile Partnering Model A small team enables flexible, fast-cycle collaboration terms and close, focused deal discussions, which can be attractive to larger pharma seeking nimble partnerships in neurology assets.

Revenue Growth Opportunity With current revenue in the low tens of millions, strategic licensing or co-development deals could provide scale and commercialization support for the pipeline.